3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Motor Activity
21
Neoplasms
13
Breast Neoplasms
8
Lung Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
3
Lymphoma
3
Recurrence
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcopenia
1
Rectal Neoplasms
1
Quality of Life
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Neurocognitive Disorders
1
Neoplasms, Plasma Cell
1
Muscular Atrophy
1
Melanoma
1
Interventions
pembrolizumab
57
Nivolumab
50
Ipilimumab
31
Specimen Handling
23
Magnetic Resonance Spectroscopy
19
Cyclophosphamide
14
Biopsy
11
fludarabine
10
binimetinib
10
Opdualag
10
trametinib
9
relatlimab
9
Radiosurgery
9
CTLA-4 Antigen
9
dabrafenib
8
lifileucel
7
fludarabine phosphate
7
aldesleukin
7
encorafenib
6
Interleukin-2
6
cemiplimab
5
atezolizumab
5
Paclitaxel
5
Blood Specimen Collection
5
X-Rays
4
Taxes
4
Pemetrexed
4
Gemcitabine
4
Cisplatin
4
Carboplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Exercise
×
90 days
×
Clear all
NCT06694571
2026-04-03
STARS
University of Utah
Phase NA
Completed
38 enrolled
9 charts